Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teneligliptin in T2DM Inadequately Controlled with Metformin and Empagliflozin
NCT05504239Phase 3Completed
- Sponsor
- Handok
- Start
- Sep 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of teneligliptin in type 2 diabetes mellitus (T2DM), sponsored by Handok. Started Sep 2022; status: completed.
02
Drugs
teneligliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05504239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504239.